These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 27696192

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.
    Okamoto M, Okamoto M, Gotoh K, Masaki T, Ozeki Y, Ando H, Anai M, Sato A, Yoshida Y, Ueda S, Kakuma T, Shibata H.
    J Diabetes Investig; 2016 Nov; 7(6):915-918. PubMed ID: 27181090
    [Abstract] [Full Text] [Related]

  • 5. Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes.
    Miyoshi Y, Ogawa O, Oyama Y.
    Tohoku J Exp Med; 2016 Jun; 239(2):155-8. PubMed ID: 27297738
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma.
    Sakaguchi C, Ashida K, Yano S, Ohe K, Wada N, Hasuzawa N, Matsuda Y, Sakamoto S, Sakamoto R, Uchi H, Furue M, Nomura M, Ogawa Y.
    Curr Oncol; 2019 Feb; 26(1):e115-e118. PubMed ID: 30853818
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Nivolumab-induced acute-onset type 1 diabetes mellitus as an immune-related adverse event: A case report.
    Hatakeyama Y, Ohnishi H, Suda K, Okamura K, Shimada T, Yoshimura S.
    J Oncol Pharm Pract; 2019 Dec; 25(8):2023-2026. PubMed ID: 30526346
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Intrinsic insulin secretion capacity might be preserved by discontinuing anti-programmed cell death protein 1 antibody treatment in 'anti-programmed cell death protein 1 antibody-induced' fulminant type 1 diabetes.
    Sakai G, Saito D, Nakajima R, Hatano M, Noguchi Y, Kurihara S, Katayama S, Inoue I, Noda M, Shimada A.
    J Diabetes Investig; 2018 Mar; 9(2):448-449. PubMed ID: 29504279
    [Abstract] [Full Text] [Related]

  • 15. Acute-onset diabetes mellitus with ketoacidosis in a nivolumab-treated patient with hepatocellular carcinoma.
    Harsch IA, Konturek PC.
    Wiad Lek; 2018 Mar; 71(5):945-948. PubMed ID: 30176620
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.